| Page 5 | Aplastic Anemia and MDS International Foundation

Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemia

Author(s): 
Zhao X, Feng X, Wu Z, Winkler T, Desmond R, Olnes M, Dumitriu B, Townsley DM, Dunbar CE, Young NS
Primary Author: 
Zhao X
Journal Title: 
Exp Hematol
Original Publication Date: 
Sep 2017

Although hematopoietic growth factors are at high levels in

Bone Marrow Diseases: 

Clinical trial reveals genetic fault that reduces the effectiveness of leukemia treatment

Author(s): 
University of Birmingham
Primary Author: 
University of Birmingham
Journal Title: 
Science Codex
Original Publication Date: 
Sep 2017

A genetic fault has been identified in people with an aggressive type of leukaemia that can significantly affect how they respond to treatment.

Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes

Author(s): 
Nazha A, Al-Issa K, Przychodzen B, Abuhadra N, Hirsch C, Maciejewski JP, Sekeres MA
Primary Author: 
Nazha A
Journal Title: 
Blood Cancer J
Original Publication Date: 
Sep 2017

No abstract available.

Bone Marrow Diseases: 

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

Author(s): 
Platzbecker U, Germing U, Götze KS, Kiewe P, Mayer K, Chromik J, Radsak M, Wolff T, Zhang X, Laadem A, Sherman ML, Attie KM, Giagounidis A
Primary Author: 
Platzbecker U
Journal Title: 
Lancet Oncol
Original Publication Date: 
Sep 2017

BACKGROUND:

Bone Marrow Diseases: 

Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R

Author(s): 
Tefferi A, Lasho TL, Patnaik MM, Saeed L, Mudireddy M, Idossa D, Finke C, Ketterling RP, Pardanani A, Gangat N
Primary Author: 
Tefferi A
Journal Title: 
Am J Hematol
Original Publication Date: 
Sep 2017

A 27-gene panel was used for next-generation sequencing (NGS) in 179 patients (median age 73 years) with primary

Bone Marrow Diseases: